Statin Therapy to Reduce the Risk of Recurrent Pancreatitis
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 8
- 试验地点
- 5
- 主要终点
- Change in Peak Bicarbonate Concentration, Measured Using Endoscopic Pancreatic Function Test (ePFT)
研究概览
简要总结
This randomized phase II trial studies how well simvastatin works in reducing pancreatitis (the inflammation of the pancreas) in patients with pancreatitis that occurs more than once (recurrent), has worsened quickly (acute), or has persisted or progressed over a long period of time (chronic). Simvastatin may decrease the inflammation of the pancreas by modulating the immune response responsible for inflammation. It is not yet known if simvastatin may be an effective treatment for pancreatitis.
详细描述
PRIMARY OBJECTIVE:
I. To evaluate the effect of a simvastatin intervention versus placebo on the change in secretin-stimulated peak bicarbonate concentration in the pancreatic fluid at 6 months post-treatment in patients with a history of at least two episodes of acute pancreatitis in the past 12 months.
SECONDARY OBJECTIVES:
I. To evaluate the effect of a simvastatin intervention versus placebo at 6 months from baseline (study visit
- on: Ia. Change in the endoscopic ultrasound score (EUS). Ib. Change in serum and pancreatic fluid levels of cytokines, chemokines, and adhesion molecules.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At least two episodes of acute pancreatitis in the past 12 months; acute pancreatitis is defined any 2 of the following: (1) typical upper abdominal pain; (2) elevation in serum amylase or lipase >= 3 times upper limit of normal; (3) features of acute pancreatitis on cross-sectional imaging
- •Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)
- •Leukocytes >= 2,500/microliter
- •Absolute neutrophil count >= 1,500/microliter
- •Platelets >= 100,000/microliter
- •Hemoglobin > 10 g/dL
- •Total bilirubin =< 3.0 x institutional upper limit of normal (ULN)
- •Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 1.5 x institutional ULN; patients whose AST/ALT levels normalize by screen 2 after an abnormal test will be included in the trial
- •Creatinine < 1.5 mg/dL
- •Women of child-bearing potential must have a confirmed negative pregnancy test result prior to enrollment
- •The effects of simvastatin on the developing human fetus at the recommended therapeutic dose are unknown; for this reason and because statins are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately; it is not known whether simvastatin is excreted into human milk; however, a small amount of another drug in this class does pass into breast milk; because statins have the potential for serious adverse reactions in nursing infants, women who receive treatment with simvastatin should not breastfeed their infants
- •Ability to understand and the willingness to sign a written informed consent document and medical release
- •Willing and able to comply with trial protocol and follow-up
排除标准
- •Prior or current use of statin medication, or current use of gemfibrozil, cyclosporine, danazol, lomitapide, verapamil, diltiazem, dronedarone, amiodarone, amlodipine, ranolazine, or strong cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, human immunodeficiency virus [HIV] protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone, or cobicistat-containing products)
- •History of chronic myopathy
- •Current use of any other investigational agents
- •History of adverse effects, intolerance, or allergic reactions attributed to compounds of similar chemical or biologic composition to simvastatin (i.e., other statin medications)
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- •Women who are pregnant or breastfeeding; pregnant women are excluded from this study because simvastatin is a lipid-lowering agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with simvastatin, breastfeeding should be discontinued if the mother is treated with simvastatin
- •Presence of gallstones and hypertriglyceridemia (level greater than 800 mg/dl) that requires medical or surgical intervention; note: we will include patients who had an independent episode of pancreatitis after a cholecystectomy, but exclude patients who are candidates for cholecystectomy
- •History of pancreatic adenocarcinoma (at any time)
- •History of active malignancy in the past 2 years (excluding basal/squamous cell skin cancer or prostate cancer with a Gleason score 6 or less)
- •Known active infection with HIV
- •Concurrent illness, such as known psychiatric disorders or substance abuse (i.e., average alcohol consumption of more than 5 drinks per day), which in the opinion of the investigators would compromise either the patient or the integrity of the data
- •Laboratory (lab) results do not meet inclusion criteria
- •Recurrent pancreatitis episode is iatrogenic (endoscopic retrograde cholangiopancreatography [ERCP] induced)
- •Advanced chronic pancreatitis as determined by the following criteria: EUS score greater than 6, calcifications in combination with atrophy and/or dilation of >= 5 mm, or evidence of advanced chronic pancreatitis by computed tomography (CT) or magnetic resonance imaging (MRI) results in the past 12 months
研究组 & 干预措施
Arm II (placebo)
Patients receive placebo PO QD for 6 months.
干预措施: Laboratory Biomarker Analysis (Other)
Arm I (simvastatin)
Patients receive simvastatin PO QD for 6 months.
干预措施: Simvastatin (Drug)
Arm I (simvastatin)
Patients receive simvastatin PO QD for 6 months.
干预措施: Laboratory Biomarker Analysis (Other)
Arm I (simvastatin)
Patients receive simvastatin PO QD for 6 months.
干预措施: Quality-of-Life Assessment (Other)
Arm I (simvastatin)
Patients receive simvastatin PO QD for 6 months.
干预措施: Questionnaire Administration (Other)
Arm II (placebo)
Patients receive placebo PO QD for 6 months.
干预措施: Placebo Administration (Other)
Arm II (placebo)
Patients receive placebo PO QD for 6 months.
干预措施: Quality-of-Life Assessment (Other)
Arm II (placebo)
Patients receive placebo PO QD for 6 months.
干预措施: Questionnaire Administration (Other)
结局指标
主要结局
Change in Peak Bicarbonate Concentration, Measured Using Endoscopic Pancreatic Function Test (ePFT)
时间窗: Baseline to up to 6 months
Change in peak bicarbonate level (mmol/l) from baseline up to 6 months. Decreased peak bicarbonate concentration indicates worsening pancreatic function.
次要结局
- Change in the Endoscopic Ultrasound Score (EUS)(Baseline to up to 6 months)
- Serum and Pancreatic Secretions(Baseline and 6 months)
- Pancreatitis-related Readmissions(Baseline to up to 6 months)
- Change in Health-related Quality of Life.(Baseline to up to 6 months)